Work

Adjuvant nivolumab (NIVO) plus ipilimumab (IPI) for resected high-risk stages IIIC/IV melanoma (MEL).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.9586

Authors: Nikhil I. Khushalani, Youngchul Kim, Geoffrey Thomas Gibney, Ragini Reiney Kudchadkar, Zeynep Eroglu, Joseph Markowitz, Maria P. Czupryn, Melissa S. Thebeau, Lori McCormick, Allison Richards, Jeffrey S. Weber

Institutions: Moffitt Cancer Center, Georgetown Lombardi Comprehensive Cancer Center, Emory University, Winship Cancer Institute, NYU Langone Health

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891505315

Cites:

Cited by: 10

Related to: 10